Pluri Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Pluri Inc (PLUR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Pluri Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 6,341M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+31.9% annualized vs trailing 12 months), vs accelerating (+14.5%) for its tracked peer group.
- Growth: Pluri Inc generated -15.8% revenue growth year over year in Q4 2026, vs 31.8% for its tracked competitors combined.
- Profitability: Its -1,848.7% net margin compares with -54.3% for the peer group.
- Scale: Pluri Inc ranks #141 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
- Peer revenue share: Pluri Inc accounted for 0.0% of combined revenue among its tracked peer group, down from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.01M compares with $0.28M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PLUR Sales vs. its Competitors, Q4 2026
Pluri Inc reported revenue contraction of 15.83 % year on year in Q4 2026, below its competitors' combined revenue growth of 31.79 %.
With a net margin of -1,848.66 %, Pluri Inc reported lower profitability than its competitors (-54.32 %).
Pluri Inc generated 0.02 % of the combined sales of its peer group, down from 0.03 % a year earlier.
Pluri Inc vs. its Competitors, Q4 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Pluri Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Pluri Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (6) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (2) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Pluri Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs -15.8% for Pluri Inc. Pluri Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Pluri Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Pluri Inc | No | No | No | Yes |
| Competitors combined (38) | ||||
| High-Confidence Competitors (4) | ||||
| Similar-Size Competitors (9) | - | - | - | |
| Similar Growth & Profitability (8) | 0.00 % (0 of 7) | 12.50 % (1 of 8) | 0.00 % (0 of 8) | 75.00 % (6 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PLUR Stock Performance relative to its Competitors
PLUR Stock Performance relative to High-Confidence Competitors
PLUR Stock Performance relative to Similar-Size Competitors
PLUR Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Relay Therapeutics Inc | 282.9% | Outperformed |
| 2 | Century Therapeutics inc | 282.9% | Outperformed |
| 3 | Replimune Group Inc | 282.9% | Outperformed |
| 4 | Krystal Biotech Inc | 282.9% | Outperformed |
| 5 | Charles River Laboratories International inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Pluri Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Pluri Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Pluri Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Pluri Inc | 9.45 | 1.02 |
| Biontech Se | 23,947.64 | 3,214.29 |
| Charles River Laboratories International inc | 14,146.51 | 3,998.99 |
| Krystal Biotech Inc | 10,333.86 | 440.48 |
| Crispr Therapeutics Ag | 5,220.45 | 13.39 |
| Relay Therapeutics Inc | 3,588.41 | 0.70 |
| SUBTOTAL | 77,513.58 | 9,695.00 |
Sign in to see all competitors of Pluri Inc .
Sources: Pluri Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Pluri Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Pluri Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Charles River Laboratories International, Inc. | Named by the company | 85% |
| Scinai Immunotherapeutics Ltd | Named by the company | 85% |
| AGC Biologics A/S | Named by the company | 85% |
| California Cultured, Inc. | Named by the company | 85% |
| Future Meat | Named by the company | 85% |
| Gourmey | Named by the company | 85% |
| Tnuva | Named by the company | 85% |
| Ayana Bio LLC | Named by the company | 85% |
| DSM Firmenich AG | Named by the company | 85% |
| Givaudan International SA | Named by the company | 85% |
| Mosa Meat | Named by the company | 85% |
| Aleph Farms | Named by the company | 85% |
| GEA | Named by the company | 85% |
| Kokomodo | Named by the company | 85% |
| Upside Foods | Named by the company | 85% |
| Believer Meats | Named by the company | 85% |
| Esco Aster | Named by the company | 85% |
| GOOD Meat | Named by the company | 85% |
| Plurinuva | Named by the company | 85% |
| Ark Biotech | Named by the company | 85% |
| Coffeesai | Named by the company | 85% |
| Gelatex | Named by the company | 85% |
| Lonza Group AG | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Pluri Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Pluri Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Charles River Laboratories International inc | Discovery and Safety Assessment 59.94 % |
| Immunocore Holdings Plc | Reportable 100.00 % |
| Ginkgo Bioworks Holdings Inc | Reportable 100.00 % |
| Prime Medicine Inc | Reportable 100.00 % |
| Autolus Therapeutics Plc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Pluri Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Pluri Inc | 9 | 11,043 | -275,750 |
| Biontech Se | 23,948 | 411,719 | -162,986 |
| Charles River Laboratories International inc | 14,147 | 202,994 | -11,995 |
| Krystal Biotech Inc | 10,334 | 1,493,166 | 818,525 |
| Crispr Therapeutics Ag | 5,220 | 66,627 | -2,244,473 |
| Relay Therapeutics Inc | 3,588 | 3,620 | -1,489,776 |
| PEERS TOTAL | 77,504 | 276,671 | -142,455 |
Pluri Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Charles River Laboratories International inc | United States 54.61 % |
| Krystal Biotech Inc | United States 75.19 % |
| 4d Molecular Therapeutics Inc | JP 97.05 % |
| Caribou Biosciences Inc | United States 94.16 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Pluri Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Pluri Inc's industry classification, broader than the peer set above. Market cap in millions of $.Pluri Inc ranks #141 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,331, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 226,707 | 26.02 % |
| 2 | Gilead Sciences Inc | 185,928 | 21.34 % |
| 3 | Moderna Inc | 76,517 | 8.78 % |
| 4 | Argenx Se | 63,326 | 7.27 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 141 | Pluri Inc | 10 | 0.00 % |
Market cap and industry share for the rest of Pluri Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Pluri Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 136 | Biocardia Inc | 13 | -23.44 % |
| 137 | Zivo Bioscience Inc | 13 | -74.62 % |
| 138 | Genenta Science S p a | 13 | -77.88 % |
| 139 | Brainstorm Cell Therapeutics inc | 11 | 37.14 % |
| 140 | Intensity Therapeutics Inc | 1,234 | 12.3% |
| 141 | Pluri Inc | 10 | -77.53 % |
| 142 | Senti Biosciences Holdings Inc | 1,234 | 12.3% |
| 143 | Futuretech Ii Acquisition Corp | 1,234 | 12.3% |
| 144 | Agomab Therapeutics Nv | 1,234 | 12.3% |
| 145 | Pharmacyte Biotech Inc | 1,234 | 12.3% |
| 146 | Liminatus Pharma Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Pluri Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Pluri Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (93 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 44.59 % | 68.46 % (avg) | -23.9 pp |
| Operating Margin | -2,454.53 % | industry median | -2,249.6 pp |
| EBITDA Margin | -2,447.34 % | -0.94 % (avg) | -2,446.4 pp |
| Capital Intensity (Capex / Revenue) | - | 6.74 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Pluri Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | -2.1x | 5.1x | -7.2x |
| Return on Equity | 238.50 % | industry aggregate | 241.93 % |
| Return on Invested Capital | 473.39 % | -6.17 % (avg) | 479.56 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Pluri Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | 89.92 % | 97.49 % |
| Operating Margin | - | - | - | - | - | -6,788.24 % | -3,109.29 % | -1,857.88 % |
| Return on Invested Capital | -68.67 % | -94.12 % | -46.20 % | -40.02 % | -35.18 % | -41.21 % | -39.80 % | -164.59 % |
| P/E | - | - | - | - | - | - | 1.1x | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Pluri Inc's Strategic Group Map
Every company in Pluri Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Pluri Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Pluri Inc's BCG Growth-Share Matrix
Relative market share (vs Pluri Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Pluri Inc falls in the Question Mark quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 10.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Pluri Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,331 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Pluri Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Pluri Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Pluri Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Pluri Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Pluri Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 241.9 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+31.9% annualized vs trailing 12 months).
Weaknesses
- Operating margin 2,249.6 points below the industry median.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (52.90 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Pluri Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Pluri Inc | 0.17 | 0.45 | - |
| Biontech Se | 3.58 | 7.54 | - |
| Charles River Laboratories International inc | 0.18 | 1.34 | 0.78 |
| Krystal Biotech Inc | 5.21 | 9.38 | - |
| Crispr Therapeutics Ag | 2.51 | 16.26 | 0.16 |
| Relay Therapeutics Inc | 3.61 | 20.10 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Pluri Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Pluri Inc | Q2 2026 | -15.8 % | - |
| Biontech Se | Q4 2025 | +4.3 % | - |
| Charles River Laboratories International inc | Q2 2026 | -2.7 % | - |
| Krystal Biotech Inc | Q2 2026 | +24.1 % | +42.9 % |
| Crispr Therapeutics Ag | Q2 2026 | +1,041.4 % | - |
| Relay Therapeutics Inc | Q2 2026 | -48.3 % | - |
| PEERS TOTAL | +13.1 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Pluri Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Pluri Inc | Q2 2026 | -27.2 % | -96.4 % |
| Biontech Se | Q4 2025 | +18.6 % | -38.9 % |
| Charles River Laboratories International inc | Q2 2026 | - | -11.9 % |
| Krystal Biotech Inc | Q2 2026 | - | +87.2 % |
| Crispr Therapeutics Ag | Q2 2026 | - | +453.8 % |
| Relay Therapeutics Inc | Q2 2026 | - | - |
Pluri Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Pluri Inc | - | - | - |
| Biontech Se | - | - | - |
| Charles River Laboratories International inc | - | - | - |
| Krystal Biotech Inc | 17.65% | 19.16% | 19.34% |
| Crispr Therapeutics Ag | - | - | - |
| Relay Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Pluri Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Pluri Inc | - | 9.30 |
| Biontech Se | - | 7.45 |
| Charles River Laboratories International inc | - | 3.54 |
| Krystal Biotech Inc | 42.14 | 23.46 |
| Crispr Therapeutics Ag | - | 389.82 |
| Relay Therapeutics Inc | - | 5,163.18 |
| PEERS AVERAGE | - | 8.00 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.